Merck Press Releases

• Published on March 15, 2012 - 20:13 GMT

  Merck Partners with Academic Scientists and Biotechnology Entrepreneurs to Create the California Institute for Biomedical Research ...

  Whitehouse Station, NJ, and San Diego, March 15, 2012 - Merck, known outside the United States and Canada as MSD, today announced a collaboration to create the California Institute for Biomedical Research (Calibr), an independent, not-for-profit …

  Distribution channels: Companies
• Published on February 7, 2012 - 09:12 GMT

  Merck Provides Update on Development Program for Suvorexant, an Investigational Orexin Receptor Antagonist for the Treatment of ...

  WHITEHOUSE STATION, N.J., Feb. 6, 2012 -- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today provided an update on the development program for suvorexant, the company's investigational orexin receptor antagonist, which, if …

  Distribution channels: Companies
• Published on November 10, 2011 - 16:13 GMT

  Merck Highlights Pipeline Progress and Showcases Novel Innovations at R&D and Business Briefing

  WHITEHOUSE STATION, N.J., Nov. 10, 2011 – Merck (NYSE:MRK), known outside the United States and Canada as MSD, today is hosting a R&D and Business Briefing. "Innovation is the centerpiece of our growth strategy at Merck," said Kenneth C. …

  Distribution channels: Companies
• Published on October 5, 2011 - 19:18 GMT

  FDA Accepts New Drug Application Filing for Ridaforolimus, Investigational mTOR Inhibitor

  WHITEHOUSE STATION, N.J. & CAMBRIDGE, Mass., Oct. 5, 2011 -- Merck (NYSE:MRK), known outside the United States and Canada as MSD, and ARIAD Pharmaceuticals, Inc., (NASDAQ:ARIA), today announced that the U.S. Food and Drug Administration (FDA) has …

  Distribution channels: Companies
• Published on September 20, 2011 - 08:10 GMT

  New Data on Odanacatib, Merck's Phase III Investigational Cat-K Inhibitor for Osteoporosis, Presented at the Annual Meeting of The ...

  SAN DIEGO, Sept. 19, 2011 - New clinical and pre-clinical data on Merck's odanacatib, an investigational cathepsin K (cat-K) inhibitor for the treatment of osteoporosis in post-menopausal women, were presented at the 33 rd Annual Meeting of The …

  Distribution channels: Companies
• Published on March 31, 2011 - 20:10 GMT

  New Data Analyses with VICTRELIS™ (boceprevir), Merck's Investigational Medicine, Examined Possible Predictors of Sustained ...

  BERLIN, March 31, 2011 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease …

  Distribution channels: Companies
• Published on March 25, 2011 - 08:10 GMT

  HASH(0xa6b74a0)

  WHITEHOUSE STATION, NJ, March 24, 2011 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved an expanded age indication for ZOSTAVAX ® (Zoster …

  Distribution channels: Companies
• Published on March 9, 2011 - 13:12 GMT

  Merck Announces FDA Acceptance of New Drug Application for Investigational Ophthalmic Medication SAFLUTAN® (tafluprost)

  WHITEHOUSE STATION, N.J., March 9, 2011 -- Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the New Drug Application (NDA) for SAFLUTAN ® (tafluprost), Merck's investigational preservative-free …

  Distribution channels: Companies